Physician profile
David S Lee
NPI 1225291685
$2,706.09
in general payments reported to CMS, 2019-2025
21 companies · $922 in 2025
The $922 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $674 · 2020: $94.28 · 2021: $155 · 2022: $466 · 2023: $208 · 2024: $186 · 2025: $922.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,316.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $885.26 | 2019-2025 | |
| Janssen Biotech, INC. | $549.04 | 2019-2025 | Tremfya, Stelara |
| Pfizer INC. | $312.90 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $202.89 | 2019-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $181.33 | 2019-2025 | Xifaxan |
| Lilly USA, LLC | $81.74 | 2024-2025 | Omvoh |
| Allergan, INC. | $58.05 | 2019 | |
| Boston Scientific Corporation | $56.03 | 2022 | |
| Aimmune Therapeutics, INC. | $51.75 | 2025 | Vowst |
| Novo Nordisk INC | $51.59 | 2021 | |
| Merck Sharp & Dohme LLC | $35.04 | 2021-2022 | |
| Celgene Corporation | $33.06 | 2023 | Zeposia |
| Ardelyx, INC. | $28.19 | 2025 | Ibsrela |
| Alnylam Pharmaceuticals INC. | $27.10 | 2025 | Amvuttra |
| Intercept Pharmaceuticals, INC. | $25.29 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cook Medical LLC | $24.16 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $23.10 | 2022 | |
| Janssen Pharmaceuticals, INC | $22.13 | 2022 | |
| Daiichi Sankyo INC. | $21.17 | 2019 | |
| Mallinckrodt Hospital Products INC. | $20.34 | 2025 | Terlivaz |
| Amarin Pharma, INC. | $15.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.